Intarcia Therapeutics

Intarcia Therapeutics, Inc.
Private
Industry pharmaceutical industry
Founded Hayward, California, United States (1995 (1995))
Headquarters Boston, MA, United States
Key people
  • Kurt C. Graves (Chairman/President/CEO)
  • James M. Ahlers (Principal Finance and Accounting Officer)
  • Michelle A. Baron M.D. (Chief Medical Officer)
Products (none as of 2012)
Website www.intarcia.com
Footnotes / references
[1][2][3][4][5]

Intarcia Therapeutics is an American pharmaceutical company based in Hayward, California and incorporated under the laws of Delaware.[1][2] It was founded in 1995 under the name "BioMedicines" and changed to its present name in 2004.[1] In April 2012, the company announced its intention to relocate its headquarters to the Boston-area.[6]

In 2005, the executive leadership of Intarcia was largely vested in two people, Karling Leung and James Ahlers, President/CEO/Director and Vice President/CFO/Finance & Operations Officer, respectively.[4] By 2012, Kurt Graves had replaced Karling Leung as President and CEO.[5]

As of 2012, Intarcia is engaged in development of a "potential once-a-year type 2 diabetes treatment". Referred to as ITCA-650, the therapeutic consists of exenatide delivered via its DUROS system,[7] "a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides".[1]

Investors

In November 2012, Intarcia received $210M in preferred stock and debt financing from, The Baupost Group, Farallon Capital Management, New Enterprise Associates, New Leaf Venture Partners and Venrock Associates. [8] Other Investors include Greenspring Associates ,[9] Alta Partners and Granite Venture Partners.

Notes

  1. 1 2 3 4 "Company Overview of Intarcia Therapeutics, Inc.", Bloomberg Businessweek, retrieved November 15, 2012
  2. 1 2 Exhibit 4.1, SEC, retrieved November 15, 2012
  3. ↑ Radius Health, Inc. (FORM S-1), SEC, February 6, 2012, retrieved November 15, 2012
  4. 1 2 "INTARCIA THERAPEUTICS, INC.", AMENDMENT NO. 1 TO FORM S-1 (SEC), March 18, 2005, retrieved November 15, 2012
  5. 1 2 Ron Leuty (November 15, 2012), "Intarcia raises $210M as it pushes once-a-year diabetes treatment into Phase III, moves HQ to Boston area", San Francisco Business Times, retrieved November 15, 2012
  6. ↑ Don Seiffert (November 15, 2012), "Intarcia, in midst of move to Boston, raises $210M", Mass High Tech (American City Business Journals), retrieved November 15, 2012
  7. ↑ "Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes Mellitus", ClinicalTrials.gov, May 1, 2012, retrieved November 15, 2012
  8. ↑ "AtTaIntarcia raises $210M as it pushes once-a-year diabetes treatment into Phase III, moves HQ to Boston area". BizJournals. November 15, 2012. Retrieved November 7, 2013.
  9. ↑ "Direct Investments". Greenspring Associates. 2013-11-07. Retrieved 2013-11-07.
This article is issued from Wikipedia - version of the Wednesday, July 15, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.